Salarius reports 43% ORR for seclidemstat combo in MDS/CMML at EHA 2024

Decoy Therapeutics Inc.

Seclidemstat + azacitidine: 43% overall response rate (6/14 evaluable) in higher-risk MDS/CMML patients who failed HMA therapy.
Median overall survival 18.5 months (95% CI 6.1-30.9) vs typical 4-6 months after HMA failure; median event-free survival 7.2 months.
Phase 1/2 dose-escalation enrolling Cohort 5 (750mg BID) and planned Cohort 6 (900mg BID); MTD not yet reached.
Dose-limiting toxicity observed in 1 patient at 750mg BID; cohort expanded per protocol; adverse events deemed manageable.
Data presented by MD Anderson investigator at European Hematology Association meeting June 13-16, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.